|View printer-friendly version|
|BrainStorm's Abstracts on Phase 2 NurOwn® Biomarkers Accepted for Presentation at the International Symposium on ALS/MND in Boston|
HACKENSACK, N.J. and PETACH TIKVAH, Israel,
The posters will feature the analyses of chitotriosidase (CHIT-1) and microRNAs (miRNAs) in the cerebrospinal fluid (CSF) of ALS patients participating in the Phase 2 study, as biomarkers to evaluate ALS disease progression and NurOwn® treatment response.
"Our Phase 2 placebo-controlled trial demonstrated clinical activity for NurOwn® in ALS, including evidence of disease halting, and the data in these two abstracts support the mechanism of action of NurOwn®. We are pleased to have them accepted for poster presentation at the prestigious ALS/MND symposium, which is the largest medical and scientific conference specific to MND/ALS. We are committed to advancing ALS science and to the development of innovative and advanced cell therapies to meaningfully address neurological diseases," commented BrainStorm's CEO
The 28th International Symposium on ALS/MND will take place at the
Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause
View original content with multimedia:http://www.prnewswire.com/news-releases/brainstorms-abstracts-on-phase-2-nurown-biomarkers-accepted-for-presentation-at-the-international-symposium-on-alsmnd-in-boston-300563476.html